DS-1062, a TROP2-targeting ADC with a Novel DNA Topoisomerase Inhibitor

Time: 9:10 am
day: Day One

Details:

  • DXd-ADC: Widely applicable technology platform
  • Preclinical results on the mechanism of action of DS-1062
  • Updates on clinical development of DS-1062

Speakers: